The impact of comorbidities on selexipag treatment effect in patients with pulmonary arterial hypertension: insights from the GRIPHON study-Reference-Cited by-同舟云学术

The impact of comorbidities on selexipag treatment effect in patients with pulmonary arterial hypertension: insights from the GRIPHON study

Published:2021-11-21 Issue:1 Volume:24 Page:205-214
ISSN:1388-9842
Container-title:European Journal of Heart Failure
language:en
Short-container-title:European J of Heart Fail

Author:

Rosenkranz Stephan¹,Channick Richard²,Chin Kelly M.³,Jenner Bartosz⁴,Gaine Sean⁵,Galiè Nazzareno⁶,Ghofrani Hossein‐Ardeschir⁷,Hoeper Marius M.⁸,McLaughlin Vallerie V.⁹,Du Roure Camille⁴,Rubin Lewis J.¹⁰,Sitbon Olivier¹¹,Tapson Victor¹²,Lang Irene M.¹³

Affiliation:

1. Heart Center University Hospital Cologne, and Cologne Cardiovascular Research Center (CCRC) Cologne Germany

2. University of California Los Angeles Los Angeles CA USA

3. UT Southwestern Medical Center Dallas TX USA

4. Actelion Pharmaceuticals Ltd Allschwil Switzerland

5. Mater Misericordiae University Hospital Dublin Ireland

6. DIMES, University of Bologna and IRCCS, S. Orsola University Hospital Bologna Italy

7. University of Giessen and Marburg Lung Center Giessen, Germany, member of the German Center for Lung Research, and Department of Medicine, Imperial College London London UK

8. Department of Respiratory Medicine Hannover Medical School and German Center for Lung Research Hannover Germany

9. University of Michigan Ann Arbor MI USA

10. Division of Pulmonary and Critical Care Medicine University of California San Diego CA USA

11. Hôpital Universitaire de Bicêtre Université Paris‐Sud Le Kremlin Bicêtre France

12. Cedars‐Sinai Medical Center Los Angeles CA USA

13. Division of Cardiology Medical University of Vienna Vienna Austria

Publisher

Wiley

Subject

Cardiology and Cardiovascular Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/ejhf.2369

Reference18 articles.

1. Pulmonary Arterial Hypertension

2. Management of pulmonary arterial hypertension in patients aged over 65 years

3. The Changing Picture of Patients With Pulmonary Arterial Hypertension in the United States

4. Changing Demographics, Epidemiology, and Survival of Incident Pulmonary Arterial Hypertension

5. Characteristics and survival of adult Swedish PAH and CTEPH patients 2000–2014

Cited by 37 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Evidence and unresolved questions in pulmonary hypertension: Insights from the 5th French Pulmonary Hypertension Network Meeting;Respiratory Medicine and Research;2024-11

2. The latest definition and classification of pulmonary hypertension;International Journal of Cardiology Congenital Heart Disease;2024-09

3. The impact of cardiovascular and lung comorbidities in patients with pulmonary arterial hypertension: A systematic review and meta-analysis;The Journal of Heart and Lung Transplantation;2024-09

4. Contemporary Treatment of Pulmonary Arterial Hypertension: A U.S. Perspective;American Journal of Respiratory and Critical Care Medicine;2024-09-01

5. Safety and efficacy of riociguat in patients with pulmonary arterial hypertension and cardiometabolic comorbidities: Data from interventional clinical trials;The Journal of Heart and Lung Transplantation;2024-09